BioInvent International

Declaration of Voting Results & Voting Rights Announcements • May 31, 2018

PRESS RELEASE 31 May 2018

Change in the number of shares and votes in BioInvent International AB

Lund, Sweden – 31 May 2018 – BioInvent International AB (publ) (BINV) today announced that the company's total number of shares as per 31 May 2018 amounts to 350,799,972 shares, corresponding to an equal number of votes. The increase in the number of shares and votes results from the exercise of the warrant series 2017/2018 and as a consequence, the number of shares and votes in the company has increased by 400,478 in May 2018.

Notes to editors:

About BioInvent

BioInvent International AB (OMXS: BINV) is focused on the discovery and development of novel and first-in-class immuno-regulatory antibodies to treat cancer. The Company's clinical programmes are BI- 1206, currently in a Phase I/II for non-Hodgkin's lymphoma and chronic lymphatic leukaemia and TB- 403, in cooperation with Oncurious, currently in Phase I/II for medulloblastoma. BioInvent has an exciting pre-clinical portfolio based on novel immuno-modulatory antibodies that target regulatory T cells (T-regs) and tumour-associated myeloid cells. The Company has a strategic research collaboration with Pfizer Inc. and BioInvent also works with leading academic institutions including the University of Southampton, Cancer Research UK, and Penn Medicine. BioInvent generates revenues from global partnerships, including Bayer Pharma, Daiichi Sankyo, and Mitsubishi Tanabe Pharma and from its manufacturing facility for the production of antibodies for research through to late- stage clinical trials. More information is available at www.bioinvent.se

For further information, please contact:

Björn Frendéus Acting CEO and Chief Scientific Officer +46 (0)46 286 25 45 +46 (0)708 11 25 45 bjorn.frendeus@bioinvent.com

BioInvent International AB (publ)

Co. reg. No. 556537-7263 Visiting address: Sölvegatan 41 Mailing address: 223 70 LUND Phone: +46 (0)46 286 85 50 www.bioinvent.com

This information is information that BioInvent International AB is obliged to make public pursuant to the Financial Instruments Trading Act. The information was submitted for publication at 08.00 CET on 31 May 2018.